Nimer S Alkhatib

18PUBLICATIONS
15CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Public economics - taxation and revenueMedical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Nov 12, 2024
Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi

|Oct 03, 2024
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Jul 17, 2024
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Jun 26, 2024
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs.

Nimer S Alkhatib, Eman Massad, Omar Rashdan

|Jul 26, 2023
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region.

Nimer S Alkhatib, Shiraz Halloush, Ivo Abraham

|Jun 15, 2023
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.

Hala H Halawah, Nimer S Alkhatib, Abdulaali R Almutairi

Pageof 3

Frequent Collaborators

12 joint publications

Ivo Abraham

4 joint publications

Karen MacDonald

2 joint publications

Ivo Abraham

2 joint publications

Matthias Calamia